BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 31109872)

  • 1. Dose to the bladder neck in MRI-guided high-dose-rate prostate brachytherapy: Impact on acute urinary toxicity and health-related quality of life.
    Sanmamed N; Chung P; Berlin A; Adleman J; Borg J; Lao B; Ghai S; Weersink R; Simeonov A; Rink A; Menard C; Helou J
    Brachytherapy; 2019; 18(4):477-483. PubMed ID: 31109872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of acute and late toxicities for three modern high-dose radiation treatment techniques for localized prostate cancer.
    Mohammed N; Kestin L; Ghilezan M; Krauss D; Vicini F; Brabbins D; Gustafson G; Ye H; Martinez A
    Int J Radiat Oncol Biol Phys; 2012 Jan; 82(1):204-12. PubMed ID: 21167653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute toxicity and health-related quality of life outcomes of localized prostate cancer patients treated with magnetic resonance imaging-guided high-dose-rate brachytherapy: A prospective phase II trial.
    Sanmamed N; Adleman J; Berlin A; Borg J; Lao B; Weersink R; Simeonov A; Rink A; Beiki-Ardakani A; Menard C; Chung P; Helou J
    Brachytherapy; 2023; 22(1):58-65. PubMed ID: 36414526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose to the bladder neck is not correlated with urinary toxicity in patients with prostate cancer treated with HDR brachytherapy boost.
    Ben Aicha I; Hathout L; Carignan D; Després P; Lavallée MC; Aubin S; Beaulieu L; Lacroix F; Foster W; Martin AG; Vigneault E
    Brachytherapy; 2020; 19(5):584-588. PubMed ID: 32928485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
    Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of bladder distension on doses to organs at risk in Pulsed-Dose-Rate 3D image-guided adaptive brachytherapy for locally advanced cervical cancer.
    Nesseler JP; Charra-Brunaud C; Salleron J; Py JF; Huertas A; Meknaci E; Courrech F; Peiffert D; Renard-Oldrini S
    Brachytherapy; 2017; 16(5):976-980. PubMed ID: 28694116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Toxicity and clinical outcomes of single-fraction high-dose-rate brachytherapy combined with external beam radiotherapy for high-/very high-risk prostate cancer: A dosimetric analysis of toxicity.
    Sakurai T; Takamatsu S; Shibata S; Iwata K; Taka M; Gabata T; Kumano T; Makino T; Mizokami A
    Jpn J Radiol; 2020 Dec; 38(12):1197-1208. PubMed ID: 32737768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Toxicity and Health-related Quality of Life after Single-fraction High Dose Rate Brachytherapy Boost and Hypofractionated External Beam Radiotherapy for Intermediate-risk Prostate Cancer.
    Shahid N; Loblaw A; Chung HT; Cheung P; Szumacher E; Danjoux C; Sankreacha R; Zhang L; Deabreu A; Mamedov A; Morton G
    Clin Oncol (R Coll Radiol); 2017 Jul; 29(7):412-420. PubMed ID: 28190638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose to the bladder neck is the most important predictor for acute and late toxicity after low-dose-rate prostate brachytherapy: implications for establishing new dose constraints for treatment planning.
    Hathout L; Folkert MR; Kollmeier MA; Yamada Y; Cohen GN; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2014 Oct; 90(2):312-9. PubMed ID: 25304791
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaginal Dose Is Associated With Toxicity in Image Guided Tandem Ring or Ovoid-Based Brachytherapy.
    Susko M; Craciunescu O; Meltsner S; Yang Y; Steffey B; Cai J; Chino J
    Int J Radiat Oncol Biol Phys; 2016 Apr; 94(5):1099-105. PubMed ID: 26883564
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intermediate dose-volume parameters and the development of late rectal toxicity after MRI-guided brachytherapy for locally advanced cervix cancer.
    Ujaimi R; Milosevic M; Fyles A; Beiki-Ardakani A; Carlone M; Jiang H; Lindsay P; Xie J; Gerber R; Croke J; Skliarenko J; Levin W; Han K
    Brachytherapy; 2017; 16(5):968-975.e2. PubMed ID: 28757404
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of Late Urinary Complications Following Image Guided Adaptive Brachytherapy for Locally Advanced Cervical Cancer: Refining Bladder Dose-Volume Parameters.
    Manea E; Escande A; Bockel S; Khettab M; Dumas I; Lazarescu I; Fumagalli I; Morice P; Deutsch E; Haie-Meder C; Chargari C
    Int J Radiat Oncol Biol Phys; 2018 Jun; 101(2):411-420. PubMed ID: 29559282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patient-reported outcomes and health-related quality of life in prostate cancer treated with a single fraction of high dose rate brachytherapy combined with hypofractionated external beam radiotherapy.
    Choudhury A; Arthur C; Malik J; Mandall P; Taylor C; Alam N; Tran A; Livsey J; Elliott T; Davidson S; Logue JP; Wylie J
    Clin Oncol (R Coll Radiol); 2014 Oct; 26(10):661-7. PubMed ID: 25027670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of toxicity after image-guided high-dose-rate interstitial brachytherapy for gynecologic cancer.
    Lee LJ; Viswanathan AN
    Int J Radiat Oncol Biol Phys; 2012 Dec; 84(5):1192-7. PubMed ID: 22592049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints.
    Peters M; van der Voort van Zyp J; Hoekstra C; Westendorp H; van de Pol S; Moerland M; Maenhout M; Kattevilder R; van Vulpen M
    Radiother Oncol; 2015 Nov; 117(2):262-9. PubMed ID: 26349590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Health-related Quality of Life and Toxicity After Single-fraction High-dose-rate Brachytherapy With External Beam Radiotherapy for Localized and Locally Advanced Prostate Cancer.
    Makino T; Nakashima K; Iijima M; Kawaguchi S; Nohara T; Shigehara K; Izumi K; Kadono Y; Kumano T; Mizokami A
    Anticancer Res; 2019 Jan; 39(1):477-486. PubMed ID: 30591498
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late side effects of 3T MRI-guided 3D high-dose rate brachytherapy of cervical cancer : Institutional experiences.
    Vojtíšek R; Sukovská E; Baxa J; Budíková M; Kovářová P; Fínek J
    Strahlenther Onkol; 2019 Nov; 195(11):972-981. PubMed ID: 31309266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between the changes in the EPIC QOL scores and the dose-volume histogram parameters in high-dose-rate brachytherapy combined with hypofractionated external beam radiation therapy for prostate cancer.
    Hashimoto Y; Akimoto T; Iizuka J; Tanabe K; Mitsuhashi N
    Jpn J Clin Oncol; 2015 Jan; 45(1):81-7. PubMed ID: 25425700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placement of an absorbable rectal hydrogel spacer in patients undergoing low-dose-rate brachytherapy with palladium-103.
    Taggar AS; Charas T; Cohen GN; Boonyawan K; Kollmeier M; McBride S; Mathur N; Damato AL; Zelefsky MJ
    Brachytherapy; 2018; 17(2):251-258. PubMed ID: 29241706
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.